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Résumé en
anglais
Strontium ranelate has been available as an osteoporosis treatment in Europe since
2004. This article describes a large European observational survey of the use of
strontium ranelate in clinical daily practice. A retrospective observational registry
included 32,446 women consulting for postmenopausal osteoporosis in seven
countries. Within the registry, 12,046 women were receiving strontium ranelate and
were followed up over 3 years. The baseline characteristics of the follow-up cohort
were similar to those of the whole registry cohort (age, 68.9 ± 10.3 years; body mass
index, 25.6 ± 4.3 kg/m(2); lumbar spine T-score, -2.57 ± 0.85 SD; femoral neck T-
score, -2.11 ± 0.86 SD). At baseline, 77 % of patients had at least one risk factor for
osteoporosis, and 46 % had a previous history of osteoporotic fracture. Mean
duration of follow-up was 32.0 ± 9.7 months, and treatment duration was 25.2 ±
13.7 months (24,956 patient-years of treatment). Persistence with strontium ranelate
was 80 % at 1 year, 68 % at 2 years, and 64 % at 32 months; most patients (about 80
%) reported rarely omitting a dose. At least one emergent adverse event was
reported in 2,674 (22 %) patients, most frequently gastrointestinal side effects. The
crude incidence of venous thromboembolic events was 2.1/1,000 patient-years. No
cases of hypersensitivity reactions, such as drug rash with eosinophilia and systemic
symptoms (DRESS), Steven-Johnson syndrome, or toxic epidermal necrolysis, were
reported. During follow-up, a fracture occurred in 890 patients (7 %); 429 of the
fractures were nonvertebral fractures. Our observational survey over 32 months
indicated good rates of adherence with strontium ranelate and confirmed its good
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